TBX20 and the PROK2-PROKR1 pathway-new kid on the block in angiogenesis research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Innate immune overactivation hinders nuclear reprogramming through IFN-IFNAR1 axis.Biochemistry and biophysics reports · 2026
   Article
2. Establishment and analysis of artificial neural network diagnosis model for coagulation-related molecular subgroups in coronary artery disease.Frontiers in genetics · 2024
   Article
3. Application of Machine Learning in Predicting Hepatic Metastasis or Primary Site in Gastroenteropancreatic Neuroendocrine Tumors.Current oncology (Toronto, Ont.) · 2023
   Article
4. 1,6-Hexanediol regulates angiogenesis via suppression of cyclin A1-mediated endothelial function.BMC biology · 2023
   Article
5. Vascular Regeneration in Peripheral Artery Disease.Arteriosclerosis, thrombosis, and vascular biology · 2020
   Review

Corrections and comments

• Comment on
  TBX20 Regulates Angiogenesis Through the Prokineticin 2-Prokineticin Receptor 1 Pathway.2018

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.